NCT07175233View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 27, 2025

Primary Completion Date

August 15, 2026

Study Completion Date

August 20, 2027

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

SIM0278 injection

SIM0278 injection

OTHER

Placebo

placebo

Trial Locations (2)

Unknown

Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University, Hangzhou

The First Hospital of China Medical University, Shenyang

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY